We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical and medical device companies generally agree that the FDA is doing the right thing to reevaluate its Part 11 rule, but most firms believe that the regulation should not be wiped away completely.